Navigation Links
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

e(R) (VNP40101M) treatment arm versus 9% for the control arm. Sepsis, pneumonia and infection accounted for 67% of the deaths on the treatment arm.

The most common severe adverse events (Grade 3 through 5) in both arms were hematologic, infectious, and respiratory disorders. The duration of myelosuppression, as well as the incidence of infectious and respiratory adverse events, was higher in the treatment arm as compared to the control arm.

Alan Kessman, Chief Executive Officer, said, "Although this trial was discontinued for safety reasons due to a disparity in on-study mortality between the two arms, in light of the objective response rate of the cytarabine and Cloretazine(R) (VNP40101M) arm, we believe that this combination merits further evaluation in first relapse of AML with modifications to address the observed toxicity and mortality at the studied dose and schedule."

At ASCO(R), data were presented on the first 206 patients treated on the trial. The median age was 59 years and the median duration of patients' first remission was 9.7 months. 139 patients and 67 patients were treated on the treatment arm and the control arm respectively. The demographics of the patients in the treatment arm were essentially similar to patients in the control arm across age, sex, and ECOG performance status.

Mr. Kessman added, "Now that the clinical hold has been lifted by the FDA, we have the opportunity to move forward in first relapse of AML with a revised protocol of this combination. However, our main focus at the present time continues to be on achieving registration for Cloretazine(R) (VNP40101M) in the United States in previously untreated elderly patients with de novo poor-risk AML."

The Phase III trial was a double-blind placebo-controlled randomized evaluation of a treatment arm consisting of cytarabine plus Cloretazine(R) (VNP40101M) versus a control arm regimen of cytarabine and placebo. The trial was designed to accrue patients i
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Dawn Echols’ professional ... finance, and music. This experience has honed her ... of psychology. Her professional counseling ( http://dawningphoenix.com ) ... treatment for offenders in domestic violence. , ... LLC, she enjoys counseling individuals and groups for ...
(Date:7/28/2014)... version of a surgical procedure to treat severe chronic ... 90 percent of the time in patients treated at ... Division of Plastic and Reconstructive Surgery report that more ... procedure all of whom had headaches associated with ... a year later. The team,s paper has received ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Shofner ... Operation Military June . Renowned LASIK and Cataract ... to provide significant funds and public awareness for ... retired military personnel and their families. “This was ... proudly give nearly $5,000 to a variety of ...
(Date:7/28/2014)... July 28, 2014 Ticket Down ... tickets in Miami, FL at the Sun Life Stadium ... American football between Argentina and Brazil has is one that ... worldwide, more rivalries are forming on a consistent basis. ... a new height in the recent 2014 World Cup. ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- British researchers ... spread far fewer germs around. In their experiments, ... times more germs from one person to the other ... suggest the more casual exchange might suffice as a ... The findings are published in the August issue of ...
Breaking Medicine News(10 mins):Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3
... member Adrianne Johnson needed to find a primary care physician ... to myRegence.com to compare those recommendations with feedback from other ... the Member Reviews she read on myRegence.com, Johnson was able ... but specialists, as well. , "The reviews on myRegence.com ...
... for improvement in reform proposals for small businesses , ... Business and Entrepreneurship Chair Mary Landrieu, D-La., and Ranking Member ... understand the needs of small businesses in health care reform ... , "We are here today to discuss one of the ...
... Scientists from 16 countries selected for their unconventional projects ... 20 The Bill & Melinda Gates Foundation today ... ideas for transforming health in developing countries. The ... diverse as developing an electronic nose to diagnose tuberculosis ...
... House Majority Leader Steny Hoyer, and Congressman Mark Schauer of ... afternoon in the Capitol with representatives from Easter Seals to ... pre-existing conditions. Shannon Saunders Eaton of Ohio ... told their personal stories as a testament to why we ...
... , An increasing number ... sustainability practices thanks to simplified life-cycle management ... 20 /PRNewswire/ - Carbonostics responds to the growing need ... user-friendly and cost-effective application complete with a comprehensive carbon ...
... Drug given within 4.5 hours still benefits patients, study ... plasminogen activator (tPA) treatment benefits stroke patients when used ... German researchers who said their findings provide further evidence ... three hours to 4.5 hours. , Previously published findings ...
Cached Medicine News:Health News:Regence Takes Community Approach to Provider 'Reviews' 2Health News:Regence Takes Community Approach to Provider 'Reviews' 3Health News:Landrieu, Snowe Champion Small Business Health Care Reform Efforts 2Health News:Bill & Melinda Gates Foundation Funds 76 New Ideas to Improve Global Health, From Chewing Gum to Chocolate 2Health News:Bill & Melinda Gates Foundation Funds 76 New Ideas to Improve Global Health, From Chewing Gum to Chocolate 3Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 3Health News:Food Industry: Carbonostics Responds To Sustainability Obstacles 2Health News:Food Industry: Carbonostics Responds To Sustainability Obstacles 3Health News:Food Industry: Carbonostics Responds To Sustainability Obstacles 4Health News:Stroke Treatment Window May Allow a Bit More Time 2
(Date:7/28/2014)... July 28, 2014 Southern Research Institute ... Ph.D., President and CEO of Southern Research Institute, ... Society (CRS) for the 2014-2015 term.  The inauguration ... July 12 in Chicago ... The Controlled Release Society is an ...
(Date:7/28/2014)... , July 28, 2014  A prospective study ... Sweden has validated the performance of ... and has associated volumetrically assessed breast density measurements ... Epidemiology, Biomarkers & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the ... tool for widespread breast cancer risk assessment," was ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
Breaking Medicine Technology:Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... While media worldwide report almost on a weekly ... new USDA study finds that olive polyphenols can inactivate ... many of today,s most deadly food poisoning occurrences. ... Albany, California, Western Regional Center, a group of USDA ...
... and pharmacy organizations are teaming up to promote ... mouth, a side effect commonly caused by taking ... can contribute to oral dryness, including antihistamines (for ... decongestants, pain medications, diuretics and antidepressants.  In its ...
Cached Medicine Technology:Scientists at USDA Says CREAGRI HIDROX® Effective Against Staphylococcus aureus Bacteria and Staphylococcus Enterotoxin A 2Dentists, Pharmacists Raise Awareness of Medication-Induced Dry Mouth 2Dentists, Pharmacists Raise Awareness of Medication-Induced Dry Mouth 3Dentists, Pharmacists Raise Awareness of Medication-Induced Dry Mouth 4Dentists, Pharmacists Raise Awareness of Medication-Induced Dry Mouth 5
...
...
...
Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
Medicine Products: